Recently BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry upside down. BioNTech stock has climbed 26% over four days as the ...
The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...
Evonik, whose products are used in items from animal feed and diapers to Pfizer/BioNTech's COVID-19 vaccine, expects 2024 adjusted earnings before interest, taxes, depreciation and amortisation ...
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...
The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...
The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the ...
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback